Education
About Us
Working with TipRanks
Follow Us
Novacyt S.A. (NVYTF)
:NVYTF
NVYTF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $1.25
Previous CloseN/A
Volume300.00
Average Volume (3M)0.00
Market Cap
$40.76M
Enterprise ValueN/A
Total Cash (Recent Filing)$44.06M
Total Debt (Recent Filing)€13.70M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding70,626,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Novacyt News
PremiumCompany Announcements
Novacyt’s AGM Approves Key Resolutions for Strategic Growth
PremiumCompany Announcements
Novacyt Releases 2024 Annual Report
PremiumCompany Announcements
Novacyt Provides Update on Liquidity Agreement and Total Voting Rights
PremiumCompany Announcements
Novacyt Announces Details for Upcoming AGM
PremiumCompany Announcements
Novacyt Announces In-Person AGM for June 2025
PremiumCompany Announcements
Novacyt S.A. Earnings Call: Mixed Sentiments and Strategic Moves
PremiumCompany Announcements
Novacyt Provides Monthly Liquidity Agreement UpdatePremiumCompany Announcements
Novacyt S.A. Reports Strong Revenue Growth in 2024NVYTF FAQ
What was Novacyt S.A.’s price range in the past 12 months?
Novacyt S.A. lowest stock price was $0.47 and its highest was $1.25 in the past 12 months.
What is Novacyt S.A.’s market cap?
Novacyt S.A.’s market cap is $40.76M.
When is Novacyt S.A.’s upcoming earnings report date?
Novacyt S.A.’s upcoming earnings report date is Sep 25, 2025 which is in 88 days.
How were Novacyt S.A.’s earnings last quarter?
Novacyt S.A. released its earnings results on Apr 30, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.46.
Is Novacyt S.A. overvalued?
According to Wall Street analysts Novacyt S.A.’s price is currently Overvalued.
Does Novacyt S.A. pay dividends?
Novacyt S.A. does not currently pay dividends.
What is Novacyt S.A.’s EPS estimate?
Novacyt S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt S.A. have?
Novacyt S.A. has 70,626,250 shares outstanding.
What happened to Novacyt S.A.’s price movement after its last earnings report?
Novacyt S.A. reported an EPS of -$0.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Novacyt S.A.?
Currently, no hedge funds are holding shares in NVYTF
Company Description
Novacyt S.A.
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
NVYTF Company Deck
NVYTF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, including successful site consolidation and growth in key business segments, alongside significant financial losses and exceptional costs. While strategic initiatives and R&D investments show promise for future growth, the financial challenges and loss after tax weigh heavily on the current outlook.Read More>Technical Analysis
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Euromedis Groupe SA
―
Median Technologies
―